4th Jan 2022 14:43
Verici Dx PLC - Cardiff-based kidney transplant test developer - Says the American Medical Association has granted it Current Procedural Terminology Proprietary Laboratory Analyses codes for both its Clarava and Tuteva tests. The codes are scheduled to become effective on April 1. Verici says the successful granting of the codes marks the first step on the path for commercial reimbursement.
Verici explains Current Procedural Terminology Proprietary Laboratory Analyses codes allow clinical laboratories to more specifically identify their tests. Verici's Clarava test is a pre-transplant test for the risk of early rejection and the Tuteva test is a post-transplant diagnostic focused on cellular rejection.
Current stock price: 57.80 pence, up 9.1% in London.
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Verici Dx